A Phase II Trial of Oxaliplatin and Capecitabine in the Treatment of Patients With Relapsed/Refractory Carcinoma of Unknown Primary Site
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 48
- 试验地点
- 10
- 主要终点
- Progression Free Survival
研究概览
简要总结
In this phase II trial, we will evaluate the feasibility and efficacy of the oxaliplatin/capecitabine combination in patients who have had one previous chemotherapy regimen for the treatment of carcinoma of unknown primary site. Patients who are relapsed after a previous response to treatment will be eligible, as well as those who were refractory to first-line therapy.
详细描述
All patients received treatment with oxaliplatin 130mg/m2, given intravenously on day 1 of each 21 day cycle. Capecitabine 1000mg/m2 PO BID was administered on days 1-14 of each cycle.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •To be included in this study, you must meet the following criteria:
- •Histologically confirmed carcinoma of unknown primary site
- •Progressive disease after treatment with one previous chemotherapy regimen.
- •Treatment with one previous immunotherapy or biotherapy regimen.
- •No previous treatment with oxaliplatin, capecitabine, or 5-FU.
- •Previous treatment with other platinum agents
- •Patients must have measurable or evaluable disease
- •ECOG Performance Status more than 2
- •Adequate bone marrow, liver and kidney function
- •Understand the nature of this study and give written informed consent.
排除标准
- •You cannot participate in this study if any of the following apply to you:
- •Age < 18 years
- •History of treatment of any invasive malignancy within the last 5 years
- •Coexistent medical illnesses
- •Clinically significant cardiac disease
- •Preexisting peripheral neuropathy > grade 1
- •Lack of physical integrity of the upper gastrointestinal tract
- •Pre-existing uncontrolled coagulopathy
- •Women who are pregnant or lactating
- •Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
研究组 & 干预措施
Oxaliplatin/Capecitabine
All patients received treatment with oxaliplatin 130mg/m2, given intravenously on day 1 of each 21 day cycle. Capecitabine 1000mg/m2 by mouth twice daily was administered on days 1-14 of each cycle.
干预措施: Oxaliplatin (Drug)
Oxaliplatin/Capecitabine
All patients received treatment with oxaliplatin 130mg/m2, given intravenously on day 1 of each 21 day cycle. Capecitabine 1000mg/m2 by mouth twice daily was administered on days 1-14 of each cycle.
干预措施: Capecitabine (Drug)
结局指标
主要结局
Progression Free Survival
时间窗: 18 months
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
次要结局
- Overall Survival(18 months)